Webinar Highlights

You will learn:

  • The importance of developing CAR-T enrichment strategies
  • A strategy for engineered T cell enrichment using an anti-human αβTCR antibody
  • Methods for characterizing antibodies
  • How antibody de novo sequencing works
  • How HDX epitope mapping works

Abstract

Since 2017 6 CAR-T therapies have been approved by the FDA. Over 500 clinical trials involving CAR-T are ongoing and the $2Bn market is expected to grow at over 35% year over year. It is an incredibly promising class of therapy for cancer treatment. Yet, many candidate therapies see disappointing response rates in clinical trials – perhaps resulting from poorly engineered (or non engineered) T cells persisting in the administered product and causing a conflict with the patient’s immune system. Many teams are therefore working on methods to better enrich and purify engineered T cells.

Known, high-performing and well used antibodies against useful targets on CAR-T cells can be examined for mechanism of action using proteomics and mass spectrometry. Knowledge of the antibody sequences via Next Generation Protein Sequencing (NGPS) can be useful for humanizing or otherwise engineering constructs. Rapid Epitope mapping by HDX can be useful for both epitope and paratope engineering strategies.

Speaker Bios

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 9000+ antibodies and we are eager to help you.